KLP Kapitalforvaltning AS bought a new stake in Embecta Corp. (NASDAQ:EMBC – Free Report) during the 4th quarter, according ...

Embecta has a twelve month low of $9.93 and a twelve month high of $21.48. Get Embecta alerts: Embecta (NASDAQ:EMBC – Get Free Report) last announced its earnings results on Thursday ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of Embecta (NasdaqGS:EMBC) with a Neutral recommendation.

Mizuho initiated coverage of Embecta (EMBC) with a Neutral rating and $15 price target The firm says its rating balances the company’s ...

Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

As of April 2, 2025, the average one-year price target for Embecta is $21.47/share. The forecasts range from a low of $18.38 to a high of $27.30. The average price target represents an increase of ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of Embecta (BMV:EMBC) with a Neutral recommendation. What are Other Shareholders Doing? IJR - iShares Core S&P Small-Cap ETF holds ...

PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Children and adults with type 1 diabetes had ...